Od 19.04.2018. do 22.04.2018.
Mjesto: Beograd, Srbija
It is our great pleasure to invite you to attend and actively participate in the 8th Adriatic and 5th ISPOR Chapter Serbia Congress of Pharmacoeconomics and Outcomes Research which will be held in hotel Zira (4*), in the beautiful city of Belgrade, Serbia, from April 19-22, 2018.
The main objective of this year’s Congress is to intensify and enhance professional and scientific discussions between various stakeholders about…
‘Improving Patients’ Health Outcomes by Fair, Transparent and Affordable Access to New Technologies’
The main goal of this year’s Congress is to intensify regional communication about these fast changing and highly important scientific areas of pharmacoeconomics and outcomes research, among different stakeholders in the healthcare, such as scientists and researchers, health care providers, clinicians, government officials and decision makers, as well as patients’ associations and pharmaceutical industry professionals.
We encourage your participation by submitting research podium and poster papers. As every year, we will organize half day educational course prior to the Congress and a number of plenary sessions, round table discussion, issue panels, and research presentations.
The main topics of this year’s Congress will be:
4 Future of HTA in CEE – ‘nice to have’ or ‘must have’?
4 Importance of national epidemiology data and patient registries for the quality and relevance of the national pharmacoeconomic studies and decision making
4 Readiness of CEE national health administrations to fairly assess diverse new technologies
4 Implementation of Managed Entry Agreements in Central and Eastern Europe - From Theory to Practice
4 Sustainability of secondary and tertiary hospital care financing through DRG – the role of national accreditation processes and clinical pathways
4 Importance and role of hospital management in the implementation and utilization of health economic and quality standards in decision making to ensure best treatment outcomes
4 Post approval real-world evidence and its relation to value based pricing & reimbursement of new technologies
4 Specifics of health economic studies in different therapeutic areas (CV, Rheum, etc.)
4 Sustainability of patient access to orphan drugs in CEE
4 Equity and equality of patient access to oncology treatment in CEE
4 Oncology health economic modelling; modelling separate lines of treatment vs treatment sequences
4 Health economic implications of antimicrobial resistance
4 Importance of the continuous health economics and outcomes research education for the sustainability of healthcare financing
Additional information about the congress organization including more detailed agenda can be found on the following web page: http://pharmacoeconomics-congress.eu/en/
For registration, please use the following link:
For abstract submission, please use the following link:
We are looking forward to hearing from you soon and welcoming you in April in Belgrade at the 8th Adriatic and 5th ISPOR Chapter Serbia Congress of Pharmacoeconomics and Outcomes Research!
Dragana Atanasijević, MD, MPH, MSc
President, ISPOR Chapter Serbia
Prof. Dinko Vitezić, MD, PhD
President, Croatian Society for Clinical Pharmacology and Therapeutics